Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credits: Canva
Sick days are again piling up with a respiratory disease, not COVID-19 or the flu. This disease is most likely the one Americans have not heard of. This is HMPV or human metapneumovirus. Doctors have asked people to stay vigilant as seasonal flu virus could lead to pneumonia and bronchitis, and it is spreading in California wastewater and around the country. However, as per public health officials, there is nothing to get worried at this point.
Also Read: Is There A Link Between Your Kidney Health And Other Chronic Diseases? Study Says Yes
As per the public database WasterwaterScan Dashboard, high levels of HMPV were detected across Northern California cities. The highest levels were reported in Redwood City, whereas elevated levels were found in San Francisco Bay Area and Napa's Wine Country. What's more dangerous is that this virus is without a vaccine.
The good news is that in other parts of country HMPV remains lower. However, the Centers for Disease Control and Prevention (CDC) noted that data from October 2025 shows the cases are trending up, especially during winter and spring.
Dr. Matthew Binnicker, director of the Clinical Virology Laboratory at Mayo Clinic, as reported by The Independent said, "In the late winter, early spring, it can account for five percent to 10 percent of all the respiratory infections that we diagnose in the United States. So it's definitely out there." Experts explain that other viruses like HMPV or influenza get a chance when COVID is quieter.
Read: HMPV Virus Cases Surging In California, New Jersey: Is It Dangerous?
HMPV was first discovered in 2001 and is part of the Pneumoviridae family along with the Respiratory syncytial virus (RSV).
HMPV most likely spreads from an infected person to others through:
In the US, HMPV circulates in predictable patterns each year, typically beginning in winter and lasting through spring.
The usually self-limiting and mild symptoms typically last 4 to 5 days. These include:
"The HMPV is not deadly, and there is no evidence of mortality or a severe transmission rate," former Indian Council of Medical Research (ICMR) scientist, Dr. Raman Gangakhedkar, told IANS, during the virus's outbreak in India in 2025.
“The virus may cause pneumonitis-like illness, but the mortality rates are almost unknown so far. HMPV has a global prevalence of about 4 per cent,” he added.
While no vaccine or treatment can prevent HMPV infection, to avoid the infection, individuals must:
Practice good hygiene and cover your mouth and nose with a tissue when coughing or sneezing, or use your elbow, not your hands, for it. And wash your hands properly, especially in healthcare settings.
The reason people have not heard about it before is because its symptoms are nearly indistinguishable from other respiratory infections, so often it could go undiagnosed. Furthermore, earlier the COVID cases and influenza cases sparked up, which deviated the attention from HMPV. Now, with the season gone, and increased awareness around respiratory illnesses, greater attention to viruses like HMPV is also paid.
Credit: Canva
One in seven Indians, or over 14 percent of the population, suffers from some form of mental health disorder. Amid an increasing treatment gap -- up to 90 percent -- seen in several states, especially in North India, the government today reiterated the plan of launching a second National Institute of Mental Health and Neurosciences (NIMHANS) in the northern states.
NIMHANS-2 was first announced by Finance Minister Nirmala Sitharaman during the Union Budget 2026-27, to deliver specialized care for mental health and neurological disorders in north India.
Health experts and policymakers, as part of the government-led Post-Budget Webinar series, highlighted the growing burden of mental and neurological disorders in India and also stressed the urgent need to strengthen institutional capacity to meet emerging healthcare demands.
"One in seven Indians is affected by mental health disorders, while several states continue to face a treatment gap ranging from 70 to 90 percent," the experts said.
Noting that Non-Communicable Diseases (NCDs) account for over 60 percent of deaths in the country, they added that "neurological and mental health conditions are among the leading contributors to disability-adjusted life years (DALYs)," among the citizens.
To address these, the experts called for ramping up tertiary mental health institutions and expanding specialized services.
The session, moderated by Vijay Nehra, Joint Secretary, Ministry of Health and Family Welfare, highlighted that North India currently lacks adequate tertiary neuro-psychiatric care facilities. These include areas such as:
Further, making a virtual address at the Post-Budget Webinar, Union Health Minister JP Nadda also highlighted the government’s focus on strengthening mental healthcare services in the country.
"NIMHANS-2 will be established in North India to expand advanced clinical care, training, and research," Nadda said.
"In addition, the Central Institute of Psychiatry, Ranchi, and the Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, will be upgraded as regional apex institutions to strengthen mental healthcare services in the eastern and north-eastern regions," he added.
Meanwhile, the experts also stressed the need to improve services in underserved and geographically remote regions, including the northeastern states, through better infrastructure, capacity building, and targeted deployment of trained mental health professionals.
They also discussed strategies for expanding advanced neuro-psychiatric care and reinforcing India’s overall mental healthcare ecosystem. They proposed:
This would allow tertiary institutions and centers of excellence to provide technical guidance, specialist consultations, and clinical support to district hospitals and community-level health facilities.
"Such a model would strengthen referral pathways and ensure that specialized mental health services are accessible to people even in remote and rural areas," the experts said.
Both existing and upcoming campuses of NIMHANS must be integrated , as this will enable a robust nationwide tele-mental health network that ensures
The experts called for the seamless integration of healthcare facilities, aligned with the vision of the Ayushman Bharat Digital Mission and the ABHA ID ecosystem. This, they said, will
The Network proposed under the National Health Mission would connect premier institutions such as All India Institute of Medical Sciences (AIIMS), state medical colleges, and primary healthcare centers through a digitally integrated platform.
It could also facilitate
Credit: Canva
California and New Jersey in the US are seeing an uptick in cases of human metapneumovirus (HMPV) -- a virus with no vaccine or treatment.
According to the US Centers for Disease Control and Prevention (CDC), HMPV can cause upper and lower respiratory disease. There is currently no vaccine to prevent it, and no specific antiviral therapy to treat it.
"Most people will recover on their own," the agency noted, but advised people who get sick to drink plenty of liquids, stay home, and rest.
As per the CDC's respiratory dashboard, the cases of HMPV steadily ticked up since November 2025. It accounted for over 5 percent of positive tests the week of February 14 through February 21.
While HMPV is not a "new" virus, having first been discovered in 2001, cases haven't spiked to this level in the US since an outbreak in April 2025, USA Today reported.
The New Jersey Respiratory Surveillance Report cited that about 4 percent of residents in the state are testing positive for HMPV. The HMPV cases, accompanied by RSV, COVID, and flu cases, are surging, increasing the number of people seeking emergency medical care.
As per the public database, WastewaterScan Dashboard, HMPV is rampant in Northern California -- specifically San Francisco, Marin, Vallejo, Napa, Novato, Santa Rosa, Sacramento, and Davis, the Independent UK reported.
HMPV was first discovered in 2001 and is part of the Pneumoviridae family along with the Respiratory syncytial virus (RSV).
HMPV most likely spreads from an infected person to others through:
In the US, HMPV circulates in predictable patterns each year, typically beginning in winter and lasting through spring.
The usually self-limiting and mild symptoms typically last 4 to 5 days. These include:
People at risk include:
"The HMPV is not deadly, and there is no evidence of mortality or a severe transmission rate," former Indian Council of Medical Research (ICMR) scientist, Dr. Raman Gangakhedkar, told IANS, during the virus's outbreak in India in 2025.
“The virus may cause pneumonitis-like illness, but the mortality rates are almost unknown so far. HMPV has a global prevalence of about 4 per cent,” he added.
While no vaccine or treatment can prevent HMPV infection, to avoid the infection, individuals must:
Practice good hygiene and cover your mouth and nose with a tissue when coughing or sneezing, or use your elbow, not your hands, for it. And wash your hands properly, especially in healthcare settings.
© 2024 Bennett, Coleman & Company Limited